[go: up one dir, main page]

FR2747920B1 - Compositions pharmaceutiques a enrobage enterique - Google Patents

Compositions pharmaceutiques a enrobage enterique

Info

Publication number
FR2747920B1
FR2747920B1 FR9704496A FR9704496A FR2747920B1 FR 2747920 B1 FR2747920 B1 FR 2747920B1 FR 9704496 A FR9704496 A FR 9704496A FR 9704496 A FR9704496 A FR 9704496A FR 2747920 B1 FR2747920 B1 FR 2747920B1
Authority
FR
France
Prior art keywords
pharmaceutical compositions
enteric coated
coated pharmaceutical
enteric
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR9704496A
Other languages
English (en)
Other versions
FR2747920A1 (fr
Inventor
Barbara Haeberlin
Ching Pong Mak
Armin Meinzer
Jacky Vonderscher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26309105&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR2747920(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9607564.3A external-priority patent/GB9607564D0/en
Priority claimed from GBGB9622028.0A external-priority patent/GB9622028D0/en
Application filed by Novartis AG filed Critical Novartis AG
Publication of FR2747920A1 publication Critical patent/FR2747920A1/fr
Application granted granted Critical
Publication of FR2747920B1 publication Critical patent/FR2747920B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FR9704496A 1996-04-12 1997-04-11 Compositions pharmaceutiques a enrobage enterique Expired - Lifetime FR2747920B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9607564.3A GB9607564D0 (en) 1996-04-12 1996-04-12 Organic compounds
GBGB9622028.0A GB9622028D0 (en) 1996-10-24 1996-10-24 Organic compounds

Publications (2)

Publication Number Publication Date
FR2747920A1 FR2747920A1 (fr) 1997-10-31
FR2747920B1 true FR2747920B1 (fr) 1999-12-31

Family

ID=26309105

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9704496A Expired - Lifetime FR2747920B1 (fr) 1996-04-12 1997-04-11 Compositions pharmaceutiques a enrobage enterique

Country Status (34)

Country Link
US (3) US6025391A (fr)
EP (2) EP1221316A1 (fr)
JP (2) JP3779732B2 (fr)
CN (1) CN1104238C (fr)
AR (2) AR006583A1 (fr)
AT (2) ATE259228T1 (fr)
AU (1) AU725388B2 (fr)
BE (1) BE1010963A3 (fr)
BR (1) BR9708624A (fr)
CO (1) CO4900024A1 (fr)
CY (1) CY2243B1 (fr)
CZ (1) CZ291811B6 (fr)
DE (4) DE122004000038I1 (fr)
DK (1) DK0892640T3 (fr)
ES (2) ES2216141T3 (fr)
FR (1) FR2747920B1 (fr)
GB (1) GB2326339B (fr)
GR (1) GR1002893B (fr)
HK (2) HK1051484A1 (fr)
HU (1) HU224919B1 (fr)
ID (1) ID18663A (fr)
IE (1) IE970267A1 (fr)
IL (1) IL126431A (fr)
IT (1) IT1297045B1 (fr)
LU (1) LU91094I2 (fr)
MY (1) MY119049A (fr)
NL (1) NL300157I2 (fr)
NO (2) NO322891B1 (fr)
NZ (1) NZ332117A (fr)
PT (1) PT892640E (fr)
RU (2) RU2615397C2 (fr)
TR (1) TR199802056T2 (fr)
TW (1) TW457098B (fr)
WO (1) WO1997038689A2 (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000067773A2 (fr) * 1999-05-10 2000-11-16 Novartis Ag Composes organiques
US20030050692A1 (en) * 2000-12-22 2003-03-13 Avantec Vascular Corporation Delivery of therapeutic capable agents
GB0124953D0 (en) * 2001-10-17 2001-12-05 Novartis Ag Organic Compounds
AU2002333098B2 (en) * 2001-10-19 2006-03-16 Isotechnika Pharma Inc. Novel cyclosporin analog microemulsion preconcentrates
GB0301259D0 (en) 2003-01-20 2003-02-19 Novartis Ag Organic compounds
GB0314553D0 (en) * 2003-06-21 2003-07-30 Weatherford Lamb Electric submersible pumps
US8993599B2 (en) * 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
AR045957A1 (es) * 2003-10-03 2005-11-16 Novartis Ag Composicion farmaceutica y combinacion
EP1729797B1 (fr) * 2004-03-22 2008-09-10 Solvay Pharmaceuticals GmbH Compositions pharmaceutiques par voie orale a base de lipases, en particulier de pancreatine, contenant des tensioacitfs
US7683188B2 (en) 2004-04-26 2010-03-23 TEVA Gyógyszergyár Zártkōrūen Mūkōdō Részvénytársaság Process for preparation of mycophenolic acid and ester derivatives thereof
EP1740563A2 (fr) 2004-04-27 2007-01-10 Teva Gyógyszergyár Zártköruen Muködo Részvenytarsaság Impureté du mofétilmycophénolate
JP2008506783A (ja) * 2004-07-20 2008-03-06 テバ ジョジセルジャール ザ−トケルエン ムケド レ−スベニュタ−ルシャシャ−グ ミコフェノール酸ナトリウムの結晶形の調製方法
GB0419355D0 (en) * 2004-08-31 2004-09-29 Novartis Ag Organic compounds
WO2006086500A2 (fr) * 2005-02-08 2006-08-17 Aspreva Pharmaceuticals Sa Compositions et methodes pour traiter des maladies vasculaires, auto-immunes et inflammatoires
WO2006086498A2 (fr) * 2005-02-08 2006-08-17 Aspreva Pharmaceuticals Sa Traitement de maladies vasculaires, auto-immunes et inflammatoires, a l'aide de faibles doses d'inhibiteurs de l'impdh
UA93384C2 (ru) 2005-07-29 2011-02-10 Солвей Фармасьютикалс Гмбх Способ получения стерилизированного порошкообразного панкреатина
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US9198871B2 (en) * 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
CN1985994B (zh) * 2005-12-19 2011-01-12 康泰乐(北京)医药科技发展有限公司 改进的包含霉酚酸盐的包有肠溶衣的药物组合物
CA2640283A1 (fr) * 2006-02-13 2007-08-23 Novartis Ag Doses elevees d'acide mycophenolique (mpa)
JP2007230948A (ja) * 2006-03-02 2007-09-13 Univ Meijo 腸溶性化硬カプセル
US10072256B2 (en) * 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
SI2032712T1 (sl) * 2006-06-29 2010-06-30 Ivax Pharmaceuticals Sro Regulacija proizvodnje kislinskega metabolita
US20080182998A1 (en) * 2007-01-25 2008-07-31 Apotex Fermentation Inc. Novel crystalline mycophenolate sodium polymorph and processes to manufacture same
US20080176937A1 (en) * 2007-01-23 2008-07-24 Apotex Fermentation Inc. Novel crystalline mycophenolate sodium polymorph and processes to manufacture same
WO2008127663A1 (fr) * 2007-04-11 2008-10-23 Teva Gyógyszergyár Zártköruen Muködo Részvénytársaság Procédé de réduction du niveau d'impuretés dans une fermentation d'acide mycophénolique
MX2010001711A (es) * 2007-08-13 2010-03-11 Panacea Biotec Ltd Composiciones de liberacion extendida que comprenden micofenolato sodico y procedimientos de las mismas.
US20090130063A1 (en) * 2007-11-15 2009-05-21 Solvay Pharmaceuticals Gmbh Process for separating and determining the viral load in a pancreatin sample
EP2310008A4 (fr) * 2008-07-09 2014-03-05 Aspreva Internat Ltd Solutions de l'acide mycophenolique de sodium a ph specifiques pour le traitement de troubles oculaires
US20110086102A1 (en) * 2009-10-13 2011-04-14 Teva Pharmaceutical Industries Ltd. Delayed release compositions
EP2488173A1 (fr) * 2009-10-13 2012-08-22 Teva Pharmaceutical Industries Ltd. Compositions à libération retardée
WO2011051967A2 (fr) * 2009-10-23 2011-05-05 Alkem Laboratories Ltd Compositions pharmaceutiques contenant du mycophénolate et leurs procédés de préparation
CN103880800A (zh) * 2010-11-16 2014-06-25 北京京卫信康医药科技发展有限公司 麦考酚酸钠的新晶型及其制备方法
CN103880799A (zh) * 2010-11-16 2014-06-25 北京京卫信康医药科技发展有限公司 麦考酚酸钠的新晶型及其制备方法
GB201100786D0 (en) 2011-01-18 2011-03-02 Ems Sa Pharmaceutical compositions of immunosuppressants
WO2013041205A1 (fr) 2011-09-19 2013-03-28 Pyxirion Pharma Gmbh Nouveaux concepts thérapeutiques pour le traitement de maladies vasculaires
NZ737435A (en) 2013-03-14 2019-02-22 Alkermes Pharma Ireland Ltd Prodrugs of fumarates and their use in treating various diseases
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
WO2014167442A1 (fr) 2013-03-26 2014-10-16 Wockhardt Limited Compositions pharmaceutiques comprenant de l'acide mycophénolique ou des sels de celui-ci
US10179120B2 (en) 2014-01-06 2019-01-15 Iron Therapeutics Holdings Ag Dosage regimen of ferric trimaltol
EP3110793B1 (fr) 2014-02-24 2019-08-21 Alkermes Pharma Ireland Limited Sulfonamide et promédicaments de fumarates de sulfinamide et leur utilisation dans le traitement de diverses maladies
GB201418710D0 (en) 2014-10-21 2014-12-03 Iron Therapeutics Holdings Ag Dosage regimen
US10213411B2 (en) 2015-08-27 2019-02-26 Vijaykumar Rajasekhar Use of prodrugs of fumarates in treating heart failure diseases
US10463642B2 (en) 2016-02-01 2019-11-05 Vijaykumar Rajasekhar Methods of treating heart failure diseases using prodrugs of methyl hydrogen fumarate
KR20190131036A (ko) * 2017-03-13 2019-11-25 오카바 파마슈티컬즈 인코포레이티드 비-사람 포유동물에게 마이코페놀산 활성제를 전달하기 위한 방법 및 조성물
EP4301380A1 (fr) 2021-03-03 2024-01-10 Sana Biotechnology, Inc. Thérapies immunosuppressives destinées à être utilisées avec des thérapies cellulaires à base de cardiomyocytes, et méthodes et compositions associées
CN114028334B (zh) * 2021-12-10 2023-08-29 卓和药业集团股份有限公司 一种肺部给药的免疫抑制剂的制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1157099A (en) * 1966-09-27 1969-07-02 Ici Ltd Fermentation Process
GB1157100A (en) * 1966-09-27 1969-07-02 Ici Ltd Pharmaceutical Compositions
GB1173942A (en) * 1967-06-06 1969-12-10 Bellon Labor Sa Roger New 2,3-Dihydro-1,4-Benzoxazines
GB1158387A (en) * 1967-06-13 1969-07-16 Ici Ltd Procedure for Isolation of Mycophenolic Acid
GB1203328A (en) * 1968-06-04 1970-08-26 Ici Ltd Pharmaceutical compositions
GB1261060A (en) * 1969-09-09 1972-01-19 Ici Ltd Phthalen-1-one derivatives
US3705946A (en) * 1971-05-25 1972-12-12 Lilly Co Eli Method of treating hyperuricemia
US3825571A (en) * 1971-07-31 1974-07-23 Chugai Pharmaceutical Co Ltd Mycophenolic acid derivatives
JPS5542995B2 (fr) * 1972-02-24 1980-11-04
US3868454A (en) * 1972-08-14 1975-02-25 Lilly Co Eli Psoriasis treatment with mycophenolic acid derivatives
US3777020A (en) * 1972-08-14 1973-12-04 Lilly Co Eli Psoriasis treatment with mycophenolic acid
US4005108A (en) * 1973-04-03 1977-01-25 Research Corporation Novel anti-leukemic diterpenoid triepoxides
US3880995A (en) * 1973-05-14 1975-04-29 Lilly Co Eli Treatment of arthritis with mycophenolic acid and derivatives
US3903071A (en) * 1973-05-22 1975-09-02 Lilly Co Eli Mycophenolic acid derivatives
JPS517116A (en) * 1974-06-11 1976-01-21 Shinetsu Chemical Co Choyoseihifukuyakuzaino seizohoho
US4234684A (en) * 1979-12-11 1980-11-18 Eli Lilly And Company Method of preparing mycophenolic acid glucoside
IT1150194B (it) * 1982-02-23 1986-12-10 Chiesi Farma Spa Formulazioni farmaceutiche ad attivita'antiinfiammatoria, analgesica,antipiretica e gastroprotettiva
US4680299A (en) * 1984-04-30 1987-07-14 E.I. Du Pont De Nemours And Company 2-phenyl-4-quinolinecarboxylic acids and pharmaceutical compositions thereof
US4686234A (en) * 1985-11-27 1987-08-11 Syntex (U.S.A) Inc. Mycophenolic acid derivatives in the treatment of inflammatory diseases, in particular rheumatoid arthritis
US4725622A (en) * 1986-01-23 1988-02-16 Syntex (U.S.A.) Inc. Mycophenolic acid derivatives in the treatment of rheumatoid arthritis
US4959387A (en) * 1986-01-23 1990-09-25 Syntex (U.S.A.) Inc. Mycophenolic acid derivatives in the treatment of rheumatoid arthritis
US4727069A (en) * 1987-01-30 1988-02-23 Syntex (U.S.A.) Inc. Heterocyclic aminoalkyl esters of mycophenolic acid, derivatives thereof and pharmaceutical compositions
US4753935A (en) * 1987-01-30 1988-06-28 Syntex (U.S.A.) Inc. Morpholinoethylesters of mycophenolic acid and pharmaceutical compositions
US4847381A (en) * 1987-08-31 1989-07-11 American Cyanamid Company 2-Phenyl-4-quinoline carboxylic acids
US5135934A (en) * 1990-07-06 1992-08-04 Du Pont Merck Pharmaceutical Company 3-phenyl-5,6-dihydrobenz(c) acridine-7-carboxylic acids and related compounds as immunosuppressive agents
US5372298A (en) * 1992-01-07 1994-12-13 The Regents Of The University Of California Transient liquid phase ceramic bonding
CA2086642C (fr) * 1992-01-09 2004-06-15 Randall E. Morris Methode de traitement des maladies vasculaires hyperproliferatives
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5283257A (en) * 1992-07-10 1994-02-01 The Board Of Trustees Of The Leland Stanford Junior University Method of treating hyperproliferative vascular disease
WO1994026265A1 (fr) * 1993-05-06 1994-11-24 Pharmagenesis, Inc. Composition de 16-hydroxytriptolide et procede d'immunotherapie
US5455045A (en) * 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
US5428040A (en) * 1993-08-31 1995-06-27 The Du Pont Merck Pharmaceutical Company Carbocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents
CN1089583C (zh) * 1993-10-01 2002-08-28 辛泰克斯（美国）公司 霉酚酸2－(4－吗啉代)乙酯高剂量口服悬浮剂
AU5594794A (en) * 1993-11-08 1995-05-29 Pharmagenesis, Inc. Immunotherapy composition and method
CA2175215C (fr) * 1993-11-19 2008-06-03 Yat Sun Or Analogues semi-synthetiques de rapamycine (macrolides) utilises comme immunomodulateurs

Also Published As

Publication number Publication date
DE19781690D2 (de) 1999-04-08
NO2007004I2 (no) 2009-10-19
PT892640E (pt) 2004-06-30
HU224919B1 (en) 2006-04-28
CY2243B1 (en) 2003-07-04
IE970267A1 (en) 1997-10-22
NZ332117A (en) 2000-04-28
ES2178510A1 (es) 2002-12-16
AU725388B2 (en) 2000-10-12
DK0892640T3 (da) 2004-05-10
AR059693A2 (es) 2008-04-23
MY119049A (en) 2005-03-31
DE122004000038I1 (de) 2006-01-26
ES2178510B1 (es) 2004-08-16
NL300157I1 (nl) 2004-10-01
EP0892640B1 (fr) 2004-02-11
LU91094I2 (fr) 2004-10-11
IT1297045B1 (it) 1999-08-03
AR006583A1 (es) 1999-09-08
BR9708624A (pt) 1999-08-03
NO984728L (no) 1998-12-02
DE69727559D1 (de) 2004-03-18
AU2384397A (en) 1997-11-07
EP0892640A2 (fr) 1999-01-27
TR199802056T2 (xx) 1999-02-22
IL126431A (en) 2005-03-20
WO1997038689A2 (fr) 1997-10-23
FR2747920A1 (fr) 1997-10-31
JP3779732B2 (ja) 2006-05-31
CZ291811B6 (cs) 2003-06-18
NL300157I2 (nl) 2004-12-01
EP1221316A1 (fr) 2002-07-10
NO322891B1 (no) 2006-12-18
JP2000503665A (ja) 2000-03-28
ATE259228T1 (de) 2004-02-15
CO4900024A1 (es) 2000-03-27
NO2007004I1 (no) 2007-04-16
ID18663A (id) 1998-04-30
GB9821304D0 (en) 1998-11-25
CN1215991A (zh) 1999-05-05
CZ326798A3 (cs) 1999-01-13
RU2203659C2 (ru) 2003-05-10
ITRM970207A1 (it) 1998-10-11
GB2326339A (en) 1998-12-23
US6025391A (en) 2000-02-15
US6306900B1 (en) 2001-10-23
HK1051484A1 (zh) 2003-08-08
ES2216141T3 (es) 2004-10-16
RU2615397C2 (ru) 2017-04-04
JP2006063086A (ja) 2006-03-09
GB2326339B (en) 2000-04-19
AT408415B (de) 2001-11-26
CN1104238C (zh) 2003-04-02
HUP9903373A3 (en) 2001-05-28
TW457098B (en) 2001-10-01
WO1997038689A3 (fr) 1997-12-04
ATA905997A (de) 2001-04-15
BE1010963A3 (fr) 1999-03-02
NO984728D0 (no) 1998-10-09
IL126431A0 (en) 1999-08-17
US6172107B1 (en) 2001-01-09
HK1016490A1 (en) 1999-11-05
GR1002893B (el) 1998-04-10
DE122004000038I2 (de) 2006-04-27
HUP9903373A2 (hu) 2001-04-28
DE69727559T2 (de) 2004-12-16

Similar Documents

Publication Publication Date Title
FR2747920B1 (fr) Compositions pharmaceutiques a enrobage enterique
FI955144A0 (fi) Päällystetyt farmaseuttiset koostumukset
IS4706A (is) Lyfjasamsetningar
DK1093815T3 (da) Oral 2-methyl-thieno-benzodiazepinformulering
NO962606L (no) Farmasöytisk sammensetning
NO973612D0 (no) Nytt farmasöytisk preparat
FI20071025L (fi) Farmaseuttisia koostumuksia
MA26507A1 (fr) Compositions pharmaceutiques d'aerosol
ID24453A (id) Produk-produk terlapis
ID18352A (id) Komposisi-komposisi farmasi
DE69822172D1 (de) Levosimendanhaltige oral anzuwendende arzneizusammensetzungen
FI951316L (fi) Peroraalinen formulaatio
NO954675D0 (no) Beleggblanding
EE9900545A (et) Farmatseutiline kompositsioon
FI973229A0 (fi) Uusi farmaseuttinen koostumus
IS5184A (is) Lyfjasamsetningar
LV11727A (lv) Farmaceitiska kompozicija
PT941100E (pt) Composicoes farmaceuticas
EE200000330A (et) Farmatseutilised kompositsioonid
FI973280L (fi) Farmaseuttinen koostumus
EP0923564A4 (fr) Composes pharmaceutiques
FI973230L (fi) Uusi farmaseuttinen formulaatio
BR9605777A (pt) Composição farmacêutica
NO994436L (no) Farmasöytiske sammensetninger
NO964309D0 (no) Farmasöytisk sammensetning

Legal Events

Date Code Title Description
FC Decision of inpi director general to approve request for restoration
CP Supplementary protection certificate (spc) filed

Free format text: PRODUCT NAME: MYCOPHENOLIC ACID; NAT. REGISTRATION NO/DATE: NL 27 308 20031010; FIRST REGISTRATION: CH - 5611501 20021024

Spc suppl protection certif: 03C0042

Filing date: 20031127

CR Request for supplementary protection certificate laid open to the public (eec regulation of 18 june 1992)

Free format text: 03C0042, 20031127

Spc suppl protection certif: 03C0042

Filing date: 20031127

CP Supplementary protection certificate (spc) filed
CY Supplementary certificate of protection granted (eec regulation of 18 june 1992)

Free format text: 03C0042, 20031127, EXPIRES: 20181010

Spc suppl protection certif: 03C0042

Filing date: 20031127

SPCC Change of owner's name or address for a supplementary protection certificate

Owner name: NOVARTIS AG, CH

Free format text: PRODUCT NAME: MYCOPHENOLIC ACID; NAT. REGISTRATION NO/DATE: NL 27 308 20031010; FIRST REGISTRATION: 5611501 20021024

Spc suppl protection certif: 03C0042

Filing date: 20031127

CA Change of address

Effective date: 20140903

RP Partial renunciation

Effective date: 20140903

SPCS Registered licence for a supplementary protection certificate

Free format text: PRODUCT NAME: MYCOPHENOLIC ACID; NAT. REGISTRATION NO/DATE: NL 27 308 20031010; FIRST REGISTRATION: CH - 5611501 20021024

Spc suppl protection certif: 03C0042

Filing date: 20031127

Name of requester: NOVARTIS AG, CH

Extension date: 20171024

CL Concession to grant licences

Name of requester: NOVARTIS AG, CH

Effective date: 20150401

PLFP Fee payment

Year of fee payment: 20

SPAY Annual fee for spc paid

Free format text: PRODUCT NAME: MYCOPHENOLIC ACID; NAT. REGISTRATION NO/DATE: NL 27 308 20031010; FIRST REGISTRATION: CH - 5611501 20021024

Spc suppl protection certif: 03C0042

Filing date: 20031127

Year of fee payment: 1

Extension date: 20171024